tbuckley/cabot-search huggingface dataset:
A Randomized Trial of Pocket-Echocardiography Integrated Mobile Health Device Assessments in Modern Structural Heart Disease Clinics
Authors: Sanjeev P. Bhavnani, Srikanth Sola, David Adams, Ashwin Venkateshvaran, P.K. Dash, Partho P. Sengupta, Sanjeev Bhavnani, Srikanth Sola, Ashwin Venkateshvaran, David Adams, Partho P. Sengupta, Thomas Ryan, Jagat Narula, James Thomas, Roberto Lang, Patricia Pellikka, Voleti Choudhary, V. Ramnath Iyer, Banajit Barooah, Srikanth Sola, Reeta Varyani, Anand Lingan, Venkatesh Murugan, Prayaag Kini, Ashwin Venkateshvaran, N. Srinivas, Asha C. Barooah, G.V.R. Subbarao, C. Shivakumar, M. Subramaniyan, Shantanu P. Sengupta, Manish Bansal, Abdul Rahaman, Vijaysinh N. Patil, Narayana R. Kumar, Mohammad Y. Gahlot, Imran M. Damani, Rahul Gulati, Shreedhar S. Joshi, Sanjay Dubey, Jesu Krupa, Sara Irfan, R.B. Vidhyakar, Narendra Bidarkar, B.K. Shantesh, Swapna S. Chavan, R. Chandramohan, Vijaya Kumar, Shilpi Tirkey, Guru Prasad, Shivaprakash S. Lakshmana, Ramesh M. Malkar, V. Manjunath, Kiran Kumar Reddy, L.G. Ramesha, Sunita Kumbhalkar, Jyoti A. Thadlani, T.M. Nawaz Basha, Syed A. Hafeez, V. Leelavathi, Robin Mathews, Melissa Daubert, Jayne Cleve, Egle Burdulis, Natalie Fauss, Georgeanne Lammertin, Bharatbhushan Patel, Evelina Petrovets, Dipti Shah, Kara Thurmond, David Tomberlin, Hemavathi Umamaheswar, Ankita Kadakia
Journal: JACC. Cardiovascular imaging (2017)
Measurement of nucleotide excision repair activity and correlation with cisplatin sensitivity.
Authors: Anne Calkins, Raphael Szalat, Matija Dreze, Mathew Schnorenberg, Raphael Ceccaldi, J. Dirk Iglehart, Jean-Bernard Lazaro
Journal: Journal of Clinical Oncology (2015)

1077 Background: Nucleotide excision repair (NER) of DNA is necessary for removal of crosslinks and other damage produced by UV light, genotoxins and chemotherapies. Germline NER deficiency causes Xeroderma Pigmentosum (XP) and inevitably leads to cancer. We explored the relationships between NER, breast cancer (BC), and cisplatin, a platinum-based chemotherapy. NER removes platinum-induced DNA crosslinks. Ergo, NER deficits may contribute to sensitivity to cisplatin-based chemotherapies. Methods: We assessed NER deficiency and sensitivity to cisplatin and UV in 40+ BC cell lines, including various subtypes as presented by published sources (COSMIC database from Forbes et al, 2014, and Neve et al Cancer Subtype Study, 2006). To monitor NER we measured removal of [6-4] photoproducts from UV-irradiated cells using a DDB2 proteo-probe (Dreze et al. 2014). Data analysis was based in Prism with t-tests and correlation studies. Results: The vast majority of tested cell lines, both cancerous and non-cancerous, exhibited more than 90% removal of [6-4] photoproducts 2 hours after UV damage. In general, UV damage persisted in triple negative (TN) cell lines compared to other BC, though not statistically significant (8% damage remaining vs 2%, p > 0.05). NER deficiency did not correlate with either cisplatin or UV sensitivity, while cisplatin and UV sensitivities correlated with each other. Fundamentally, intermediate steps exist between DNA deficiency and cell death in the majority of cell lines. However, one TN cell line, MDA-MB-468, showed extreme NER deficiency equivalent to XP cells (89% damage remaining). We did not identify mutations in NER genes but found reduced XP group F protein (XPF). Complementation with wildtype XPF cDNA rescued NER activity. This cell line may represent a new subtype of DNA repair-deficient breast cancer. In addition, BRCA1 and BRCA2 gene mutation status did not correlate with NER activity. Conclusions: We propose NER deficiency is present in DNA repair-deficient breast cancer, specifically in the TN subtype. NER deficiency is oncogenic and may be a driver of cancer. Measurement of NER in breast tumors may identify patients who benefit from platinum-based therapies.
Globally optimizing therapeutic combinations against bortezomib-resistant multiple myeloma using a quantitative parabolic optimization platform (QPOP)
Authors: M. Rashid, T.B. Toh, N.L. Abdullah, A. Silva, Y. Zhang, P.F. Tan, A.L. Teh, N. Karnani, S. Jha, C-M. Ho, W.J. Chng, H. Dean, E.K-H. Chow
Journal: Annals of Oncology (2017)
Effect of Post–Cesarean Delivery Oral Cephalexin and Metronidazole on Surgical Site Infection Among Obese Women
Authors: Amy M. Valent, Chris DeArmond, Judy M. Houston, Srinidhi Reddy, Heather R. Masters, Alison Gold, Michael Boldt, Emily DeFranco, Arthur T. Evans, Carri R. Warshak
Journal: JAMA (2017)

<h3>Importance</h3> The rate of obesity among US women has been increasing, and obesity is associated with increased risk of surgical site infection (SSI) following cesarean delivery. The optimal perioperative antibiotic prophylactic regimen in this high-risk population undergoing cesarean delivery is unknown. <h3>Objective</h3> To determine rates of SSI among obese women who receive prophylactic oral cephalexin and metronidazole vs placebo for 48 hours following cesarean delivery. <h3>Design, Setting, and Participants</h3> Randomized, double-blind clinical trial comparing oral cephalexin and metronidazole vs placebo for 48 hours following cesarean delivery for the prevention of SSI in obese women (prepregnancy BMI ≥30) who had received standard intravenous preoperative cephalosporin prophylaxis. Randomization was stratified by intact vs rupture of membranes prior to delivery. The study was conducted at the University of Cincinnati Medical Center, Cincinnati, Ohio, an academic and urban setting, between October 2010 and December 2015, with final follow-up through February 2016. <h3>Interventions</h3> Participants were randomly assigned to receive oral cephalexin, 500 mg, and metronidazole, 500 mg (n = 202 participants), vs identical-appearing placebo (n = 201 participants) every 8 hours for a total of 48 hours following cesarean delivery. <h3>Main Outcomes and Measures</h3> The primary outcome was SSI, defined as any superficial incisional, deep incisional, or organ/space infections within 30 days after cesarean delivery. <h3>Results</h3> Among 403 randomized participants who were included (mean age, 28 [SD, 6] years; mean BMI, 39.7 [SD, 7.8]), 382 (94.6%) completed the trial. The overall rate of SSI was 10.9% (95% CI, 7.9%-14.0%). Surgical site infection was diagnosed in 13 women (6.4%) in the cephalexin-metronidazole group vs 31 women (15.4%) in the placebo group (difference, 9.0% [95% CI, 2.9%-15.0%]; relative risk, 0.41 [95% CI, 0.22-0.77];<i>P</i> = .01). There were no serious adverse events, including allergic reaction, reported in either the antibiotic group or the placebo group. <h3>Conclusions and Relevance</h3> Among obese women undergoing cesarean delivery who received the standard preoperative cephalosporin prophylaxis, a postoperative 48-hour course of oral cephalexin and metronidazole, compared with placebo, reduced the rate of SSI within 30 days after delivery. For prevention of SSI among obese women after cesarean delivery, prophylactic oral cephalexin and metronidazole may be warranted. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT01194115
A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC)
Authors: M. Hidalgo, R. Pazo-Cid, C. Guillen-Ponce, R. López, R. Vera, M. Reboredo, A. Muñoz, E. Martinez de Castro, R. Díaz Beveridge, A. La Casta, J.I. Martin-Valades, A. Cubillo, J. Martínez-Galán, I. Ales, J. Sastre, T. Macarulla Mercade
Journal: Annals of Oncology (2017)
Relatively favorable outcome after allogeneic stem cell transplantation for<i>BCR-ABL1</i>-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT)
Authors: Vladimir Lj Lazarevic, Myriam Labopin, Wu Depei, Ibrahim Yakoub‐Agha, Anne Huynh, Per Ljungman, Nicolaas Schaap, Jan J. Cornelissen, Natacha Maillard, Pietro Pioltelli, Tobias Gedde‐Dahl, Stig Lenhoff, Mohamed Houhou, Jordi Esteve, Mohamad Mohty, Arnon Nagler
Journal: American Journal of Hematology (2017)

The aim of the study was to assess the role of allogeneic stem cell transplantation (SCT) in patients diagnosed with BCR-ABL1-positive acute myeloid leukemia (AML). Fifty-seven patients (median age, 48 years, range: 19-67) with BCR-ABL1 positive AML undergoing SCT were identified. The majority of the patients (70%) received a TKI before the transplant. At SCT 48 patients were in CR (45 in CR1), while 9 patients were transplanted in a more advanced stage of the disease. MRD was negative (BCR-ABL1/ABL < 104 ) at time of SCT in 36.1% (14/40). After SCT, 16 (61.5%) out of 26 patients with MRD positive at transplantation reached MRD negativity. After a median follow-up of 6.3 years (0.7-14.2), NRM, RI, LFS, OS, and GRFS at 5 years were 18.1%, 37%, 44.2%, 53.8%, and 32.1%, respectively. The cumulative incidence of acute GvHD grade II-IV was 16.4%, incidence of chronic GvHD 24.9%, and of extensive cGvHD 21.4%, respectively. In patients who received SCT in CR1, 5-yr NRM, RI, LFS, OS, and GRFS were 15.9%, 36.4%, 46.5%, 59.4%, and 34.9%, respectively. Univariate analysis showed that age (<50 vs. ≥50 years) was associated with RI (5-yr: 22.7 vs. 50%), LFS (5-yr: 61.9 vs. 31.8%), and GRFS (5-yr: 52.4 vs. 18.2%), whereas MRD-negative status before SCT was associated with an improved GRFS (38.9 vs. 16.7%). We conclude that the outcome of patients <50 years of age with BCR-ABL1-positive AML receiving allogeneic SCT in CR is relatively favorable, possibly reflecting the beneficial effect of the use of TKI.
KRAS mutants to regulate PD-L1 expression through NF-ƘB and HIF-1α pathways in non-small cell lung cancer cells.
Authors: Rong Guo, Yong Li, Hua Bai, Jie Wang
Journal: Journal of Clinical Oncology (2017)

e20049 Background: PD-L1 (programmed death ligand 1) is expressed in various kinds of human tumors including non-small cell lung cancer (NSCLC) and is of critical importance for the immune escape of tumor cells by inhibiting T cell function via its coinhibitory receptor, programmed death 1 (PD-1). Some driver gene mutations including KRAS have been reported to be involved in intrinsic regulation of PD-L1 expression. However, the potential role and precise mechanism of KRAS mutants in regulation of PD-L1 expression in NSCLC cells remain obscure. Methods: We first examined the expression of PD-L1 and key molecules of KRAS signaling pathway in a panel of NSCLC cells with wild-type or mutant KRAS gene. Additionally, KRAS mutant transfection and pharmacological inhibitors of MEK/ERK, PI3K/AKT, and NF-κB were employed to elucidate the regulation mechanism of PD-L1 expression by KRAS mutant in NSCLC cells. We further analyzed KRAS status and protein levels of PD-L1 and hypoxia inducible factor 1 alpha (HIF-1α) in 82 cases of NSCLC tissue. Results: Examination of the KRAS signaling cascades in NSCLC cells revealed an apparent association of PD-L1 overexpression with activation of MEK/ERK and PI3K/AKT pathways. Moreover, NSCLC cells transfected with KRAS mutants and subsequently treated with pharmacological inhibitors showed strong accordance between PD-L1 expression and two transcription factors, NF-κB and HIF-1α. Further transfection or depletion of HIF-1α increased or decreased PD-L1 expression in NSCLC cells accompanied by enhanced or reduced p-IκBα level, respectively, indicating the central role of HIF-1α in upregulating PD-L1 expression in a mechanism parallel to and partially dependent on activation of the NF-κB pathway. Moreover , PD-L1 expression was detected in 31.7% of 82 NSCLC tissues and showed positive correlation with the rate of HIF-1α expression (52.4%). Conclusions: Taken together, KRAS mutants were identified to regulate PD-L1 expression by activating PI3K/AKT and MEK/ERK pathways via NF-κB and HIF-1α, suggesting the correlation between driver gene mutation and tumor immune escape in NSCLC.
Safety and efficacy of S-1 treatment in elderly patients with advanced or recurrent gastric cancer: A subgroup analysis from the phase III JFMC36-0701 trial
Authors: K. Nishikawa, S. Yoshino, S. Morita, T. Takahashi, K. Sakata, J. Nagao, H. Nemoto, N. Murakami, H. Hasegawa, R. Shimizu, T. Yoshikawa, H. Osanai, M. Imano, H. Naitoh, A. Tanaka, J. Sakamoto, S. Saji, M. Oka
Journal: Annals of Oncology (2017)
Aneurysm Formation After Stent Grafting in Vascular Behçet's Disease
Authors: Suguru Honda, Fumio Hirano, Mariko Mouri, Hisanori Hasegawa, Hitoshi Kohsaka
Journal: Arthritis & Rheumatology (2017)

A 40-year-old man with a history of oral and ileocecal ulcers, acneiform lesions, erythema nodosum and deep vein thrombosis presented with fever, abdominal pain and a pulsatile mass in the right groin. Two months prior to the presentation, he underwent stent grafting via the right femoral artery for an abdominal aortic aneurysm. Enhanced computed tomography disclosed aneurysms at the both ends of the stent (blue and green arrows in the panels A and B) and at the right femoral puncture site (blue arrowhead).

This article is protected by copyright. All rights reserved.
A novel radiomic based imaging tool to monitor tumor lymphocyte infiltration and outcome of patients treated by anti-PD-1/PD-L1
Authors: R. Sun, E.J. Limkin, L. Dercle, S. Champiat, S. Reuzé, D. Brandao, L. Verlingue, S. Ammari, S. Aspeslagh, A. Schernberg, S. Postel-Vinay, A. Hollebecque, C. Massard, A. Marabelle, C. Robert, J.-C. Soria, E. Deutsch, C. Ferté
Journal: Annals of Oncology (2017)
Hyperfractionated twice daily re-irradiation (bid re-RT) and chemotherapy (CT) for locoregionally recurrent head and neck squamous cell carcinoma (LR HNSCC): A systematic review (SR)
Authors: D. Day, G. Locke, K. Chan, S. Cheng, L. Wang, B. O'Sullivan, A.R. Hansen
Journal: Annals of Oncology (2017)
GW28-e1101 Noninvasive Left Stellate Ganglion Ablation with Trans-esophageal Ultrasonic Strategy in Canine Models
Authors: Yuanqing Yao, Jun Qian, Jie Tan, Que Zhu, Changming Deng, Dichuan Liu, Shunkang Rong, Gang Yang, Yuwen Huang, Bo Xiong, Dengqing Zhang, Shimin Deng, Jing Huang
Journal: Journal of the American College of Cardiology (2017)
Common <i>TDP1</i> Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium
Authors: Pawadee Lohavanichbutr, Lori C. Sakoda, Christopher I. Amos, Susanne M. Arnold, David C. Christiani, Michael P.A. Davies, John K. Field, Eric B. Haura, Rayjean J. Hung, Takashi Kohno, Maria Teresa Landi, Geoffrey Liu, Yi Liu, Michael W. Marcus, Grainne M. O'Kane, Matthew B. Schabath, Kouya Shiraishi, Stacey A. Slone, Adonina Tardón, Ping Yang, Kazushi Yoshida, Ruyang Zhang, Xuchen Zong, Gary E. Goodman, Noel S. Weiss, Chu Chen
Journal: Clinical Cancer Research (2017)

Purpose: DNA topoisomerase inhibitors are commonly used for treating small-cell lung cancer (SCLC). Tyrosyl-DNA phosphodiesterase (TDP1) repairs DNA damage caused by this class of drugs and may therefore influence treatment outcome. In this study, we investigated whether common TDP1 single-nucleotide polymorphisms (SNP) are associated with overall survival among SCLC patients.Experimental Design: Two TDP1 SNPs (rs942190 and rs2401863) were analyzed in 890 patients from 10 studies in the International Lung Cancer Consortium (ILCCO). The Kaplan-Meier method and Cox regression analyses were used to evaluate genotype associations with overall mortality at 36 months postdiagnosis, adjusting for age, sex, race, and tumor stage.Results: Patients homozygous for the minor allele (GG) of rs942190 had poorer survival compared with those carrying AA alleles, with a HR of 1.36 [95% confidence interval (CI): 1.08-1.72, P = 0.01), but no association with survival was observed for patients carrying the AG genotype (HR = 1.04, 95% CI, 0.84-1.29, P = 0.72). For rs2401863, patients homozygous for the minor allele (CC) tended to have better survival than patients carrying AA alleles (HR = 0.79; 95% CI, 0.61-1.02, P = 0.07). Results from the Genotype Tissue Expression (GTEx) Project, the Encyclopedia of DNA Elements (ENCODE), and the ePOSSUM web application support the potential function of rs942190.Conclusions: We found the rs942190 GG genotype to be associated with relatively poor survival among SCLC patients. Further investigation is needed to confirm the result and to determine whether this genotype may be a predictive marker for treatment efficacy of DNA topoisomerase inhibitors. Clin Cancer Res; 23(24); 7550-7. ©2017 AACR.
microRNA(miR) subtypes correlates with colorectal cancer(CRC) molecular subtypes: Validation of miR-30b interaction with genes up-regulated in the high-stroma subtype
Authors: B. Perez-Villamil, M. Paz-Cabezas, T. Calvo-López, J. Ogando-Castro, J. Sastre, S. Mañes, E. Díaz-Rubio
Journal: Annals of Oncology (2017)
Authors' reply: Estimating the impact of the 2009 influenza A(H1N1) pandemic on mortality in the elderly in Navarre, Spain
Authors: J Castilla, J Etxeberria
Journal: Eurosurveillance (2010)

Preview this article: Authors' reply: Estimating the impact of the 2009 influenza A(H1N1) pandemic on mortality in the elderly in Navarre, Spain, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/15/9/art19502-en-1.gif
Effect of a Game-Based Intervention Designed to Enhance Social Incentives to Increase Physical Activity Among Families
Authors: Mitesh S. Patel, Emelia J. Benjamin, Kevin G. Volpp, Caroline S. Fox, Dylan S. Small, Joseph M. Massaro, Jane J. Lee, Victoria Hilbert, Maureen Valentino, Devon H. Taylor, Emily S. Manders, Karen Mutalik, Jingsan Zhu, Wenli Wang, Joanne M. Murabito
Journal: JAMA Internal Medicine (2017)

Gamification, the application of game design elements such as points and levels in nongame contexts, is often used in digital health interventions, but evidence on its effectiveness is limited.To test the effectiveness of a gamification intervention designed using insights from behavioral economics to enhance social incentives within families to increase physical activity.The Behavioral Economics Framingham Incentive Trial (BE FIT) was a randomized clinical trial with a 12-week intervention period and a 12-week follow-up period. The investigation was a community-based study between December 7, 2015, and August 14, 2016. Participants in the modified intent-to-treat analysis were adults enrolled in the Framingham Heart Study, a long-standing cohort of families.All participants tracked daily step counts using a wearable device or a smartphone, established a baseline, selected a step goal increase, and received daily individual feedback on goal performance by text message or email for 24 weeks. Families in the gamification arm could earn points and progress through levels based on physical activity goal achievement during the 12-week intervention. The game design was meant to enhance collaboration, accountability, and peer support.The primary outcome was the proportion of participant-days that step goals were achieved during the intervention period. Secondary outcomes included the proportion of participant-days that step goals were achieved during the follow-up period and the change in the mean daily steps during the intervention and follow-up periods.Among 200 adults comprising 94 families, the mean age was 55.4 years, and 56.0% (n = 112) were female. During the intervention period, participants in the gamification arm achieved step goals on a significantly greater proportion of participant-days (0.53 vs 0.32; adjusted difference, 0.27; 95% CI, 0.20-0.33; P < .001) and had a significantly greater increase in the mean daily steps compared with baseline (1661 vs 636; adjusted difference, 953; 95% CI, 505-1401; P < .001) than the control arm. During the follow-up period, physical activity in the gamification arm declined but remained significantly greater than that in the control arm for the proportion of participant-days achieving step goals (0.44 vs 0.33; adjusted difference, 0.12; 95% CI, 0.05-0.19; P < .001) and the mean daily steps compared with baseline (1385 vs 798; adjusted difference, 494; 95% CI, 170-818; P < .01).Gamification designed to leverage insights from behavioral economics to enhance social incentives significantly increased physical activity among families in the community.clinicaltrials.gov Identifier: NCT02531763.
GSTP1 c.313A&gt;G, XPD c.934G&gt;A, XPF c.2505T&gt;C and CASP9 c.-1339A&gt;G polymorphisms and severity of vomiting in head and neck cancer patients treated with cisplatin chemoradiation
Authors: C.S.P. Lima, J. Carron, L. Lopes-Aguiar, E.F.D. Costa, G.A.S. Nogueira, T.R.P. Lima, E.C. Pincinato, M.B. Visacri, J.C.F. Quintanilha, P. Moriel, G.J. Lourenço
Journal: Annals of Oncology (2017)
Multicenter, nonrandomized, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy: results in malignant pleural mesothelioma (MPM)
Authors: J.M. Trigo Perez, E. van Brummelen, E. Levchenko, M. Domine Gomez, D.A. Fennell, H.L. Kindler, S. Viteri, S. Gadgeel, P. Garrido Lopez, V. Kostorov, D. Morgensztern, S. Orlov, P.K. Paik, J.F. Vansteenkiste, X. Wang, A. Sharabidze, M.P. Deyoung, K.P. Baker, L. Yan, I. Mitrica
Journal: Annals of Oncology (2017)
PEGylated TRAIL ameliorates experimental inflammatory arthritis by regulation of Th17 cells and regulatory T cells
Authors: Jong-Sung Park, Yumin Oh, Ogyi Park, Catherine A. Foss, Sung Mook Lim, Dong-Gyu Jo, Dong Hee Na, Martin G. Pomper, Kang Choon Lee, Seulki Lee
Journal: Journal of Controlled Release (2017)
Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: Final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial
Authors: P.G. Casali, A. Le Cesne, A. Poveda, D. Kotasek, P. Rutkowski, P. Hohenberger, E. Fumagalli, I. Judson, A. Italiano, H. Gelderblom, N. Penel, H-G. Kopp, D. Goldstein, J. Martin Broto, A. Gronchi, E. Wardelmann, S. Marreaud, J. Zalcberg, S. Litière, J-Y. Blay
Journal: Annals of Oncology (2017)